Keywords: Rheumatoid arthritis, Biologicals, Roche, Chugai, Actemra, Roctemra, AstraZeneda, Pfizer, Decision Resources
Uptake of alternative biologics such as Roche/Chugai's Actemra/RoActemra will erode RA market share of TNF-alpha inhibitors through 2019
Article | 30 July 2010
In the rheumatoid arthritis (RA) drug market, the uptake of alternative biologics such as Roche/Chugai's Actemra/RoActemra (tocilizumab) will erode the market share of TNF-alpha inhibitors over the next decade, according to new research from Decision Resources.
A Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- GlaxoSmithKline’s Avandia still available in UK, despite MHRA call for its suspension
- Israel relaxes restrictions on medical marijuana; scientists develop new HIV/AIDS treatment
- Tough road ahead for some generics after USA’s Federal Circuit Patent Use Code decisions
- Bausch & Lomb moves to acquire Miochol-E from Novartis as required by US competition authority
- German drug price curbs will hamper orphan drug development, says BIO Deutschland
